The BioNTech SE ADR BNTX inched 0.49% higher to $118.22 Friday, on what proved to be an all-around mixed trading session for ...

BioNTech has been boosted a wave of enthusiasm over another company’s cancer drug, which has turned the biopharma industry ...

BioNTech stock has climbed 25% over four days as the German biotech rides a round of cancer treatment success from Summit ...

The autumn wave of coronavirus is sweeping across Germany. Those affected mainly suffer from coughs, colds, sore throats and ...

Health Canada approved Pfizer-BioNTech’s updated COVID-19 vaccine on Tuesday, marking its third authorization of vaccine ...

BioNTech's shares have experienced a remarkable upswing, with the stock price soaring to $130.90 on NASDAQ, marking a 6.0% increase in the latest session. This surge represents a significant ...

Upon authorization by the European Commission, the Omicron KP.2-adapted COVID-19 vaccine will be available for individuals 6 months of age and ...

In a report released yesterday, John Newman from Canaccord Genuity maintained a Buy rating on BioNTech SE (BNTX – Research Report), with ...

Discover BioNTech SE's innovative RNA lipoplex patent, detailing advanced methods for stable RNA delivery, GMP production, and effective intravenous administration.

Inflation generally hurts disposable income. This discourages consumers from buying high-priced items like furnishings and ...

The BioNTech SE ADR BNTX inched 0.69% higher to $113.05 Monday, on what proved to be an all-around positive trading session ...

Pfizer Canada says Health Canada has approved its updated COVID-19 vaccine that protects against one of the most recently ...